THE TEAM
Ina Margaretha CEO) has 25 years of experience with the fields of clinical drug development, business development, strategic partnerships, and building innovative biotech businesses in Europe.
Ina Margaretha has been building multiple start-ups, organizing funding (including European grants), leading R&D programs and commercial strategies to develop groundbreaking therapies in the field of musculoskeletal, immunology, inflammatory diseases, orphan diseases and CNS, ultimately negotiating attractive licensing deals to accelerate time to market. Beside Epione’s microsphere drug delivery platform, she worked on implantable medical devices combined with stem cells for cartilage repair and osteoarthritis.
Ina Margaretha has a Master’s Degree in Biomedical Sciences from the Leiden Medical University, The Netherlands.
Ina Margaretha has been building multiple start-ups, organizing funding (including European grants), leading R&D programs and commercial strategies to develop groundbreaking therapies in the field of musculoskeletal, immunology, inflammatory diseases, orphan diseases and CNS, ultimately negotiating attractive licensing deals to accelerate time to market. Beside Epione’s microsphere drug delivery platform, she worked on implantable medical devices combined with stem cells for cartilage repair and osteoarthritis.
Ina Margaretha has a Master’s Degree in Biomedical Sciences from the Leiden Medical University, The Netherlands.
Laura Creemers (CSO) is associate professor at the University Medical Centre Utrecht working at the forefront of preclinical research on local drug delivery in orthopaedic disease. As intervertebral disc degeneration (IVDD) and osteoarthritis (OA) (patho)biologist, she is and has been the coordinator of several large consortia on local drug delivery in OA and IVDD-associated chronic low back pain. These include Biomedical Materials-IdIDAS (IVDD) and LSH-ArIADNE, the pivotal projects that provided the preclinical evidence leading to the establishment of Epione. Given the translational nature of the research line, most of her projects entail industry as partner, ranging from SMEs to large companies such as DSM.
Leonie Middelink (COO) is a drug development executive and works and has worked as an independent consultant for multiple biopharmaceutical and academic organizations including Citryll, Audion Therapeutics, Cellpoint, Amsterdam UMC, Dutch Cancer Institute, Radboud University Medical Center, Roche, Enceladus & Arthrogen. After holding several positions at Pharmacia and Pfizer, she headed the Clinical Operations department at Roche and now has 25 years’ experience in biopharmaceutical development including leadership roles in which she was responsible for development strategy, clinical research, quality management and operations.
